Date | Price Target | Rating | Analyst |
---|---|---|---|
5/8/2024 | $12.00 | Buy | BofA Securities |
11/9/2023 | $12.00 | Buy | Deutsche Bank |
10/6/2023 | $10.00 | Outperform | Oppenheimer |
3/21/2023 | $15.00 → $8.00 | Overweight → Equal Weight | Wells Fargo |
8/18/2022 | $15.00 | Overweight | Wells Fargo |
11/17/2021 | $30.00 | Buy | Berenberg |
10-Q - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
8-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)
BofA Securities initiated coverage of Sutro Biopharma with a rating of Buy and set a new price target of $12.00
Deutsche Bank initiated coverage of Sutro Biopharma with a rating of Buy and set a new price target of $12.00
Oppenheimer initiated coverage of Sutro Biopharma with a rating of Outperform and set a new price target of $10.00
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 - - REFRαME-O1 Part 2 (randomized portion) of the Phase 3 trial of luvelta for treatment of platinum-resistant ovarian cancer (PROC) is underway - - REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) AML, is expected to be initiated in the second half of 2024 - - A Phase 2 trial of luvelta for the treatment of NSCLC is expected to initiate in the second half of 2024, with initial data expect
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., as Chief Business Development Officer, effective July 8, 2024. Dr. Leyman brings 20 years of life science industry business development, investing, and corporate strategy experience to Sutro. "We are thrilled to welcome Dr. Leyman at a pivotal time for Sutro, as we advance luvelta in two registration-directed trials in both ovarian cancer and a rare pediatric cancer and continue to leverage our proprieta
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs, targeted oncology, and novel biotherapeutic platforms. "Dr. Gerber's deep experience in the development of ADCs and other novel therapeutics make him an invaluable addition to our management team
- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002, an ADC being developed for the treatment of advanced ovarian cancer. In addition to members of the Sutro management team, the call will feature Dr. R. Wendel Naumann, Investigator in the STRO-002-GM1 stud
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) - - Luvelta in combination with bevacizumab demonstrated encouraging preliminary antitumor activity (35% response rate) across all explored dose ranges - - Expansion at RP2D is ongoing with an additional 23 patients enrolled to date; expansion data are expected in the first half of 2025 - - No new safety signals were observed compared with either agent alone - SOUTH SAN FRANCISCO, Calif., Sept. 14, 2024 (GLOBE NEWSWIRE) -- S
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET. Webcast Information:To access the live audio webcast on Thursday, October 10, at 1:30 p.m. PT / 4:30 p.m. ET, please go to https://ir.sutrobio.com/news-events/ir-calendar An archived replay of the webcast will be available on the Company's website following t
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025. "The initiation of REFRαME-L1 is an important milestone in our efforts to expand the application of luvelta to a broad range of patients with FRα expressi
SC 13G - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)
4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
3 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share. Virios Therapeutics shares dipped 47.6% to $0.1850 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers MultiMetaVerse Holdings Limited (NASDAQ:MMV) shares jumped 224% to $2.01. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries. GT Biopharma, Inc. (NASDAQ:GTBP) rose 146% to $7.64. GT Biopharma, last week, posted a narrower-than-expected quarterly loss. Tantech Hold
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Monday. Shares of Overseas Shipholding Group, Inc. (NYSE:OSG) rose sharply during Monday's session after the company announced it entered into a definitive merger agreement to be acquired by Saltchuk Resources. The transaction is valued at an aggregate equity value of around $653 million and a total transaction value of $950 million. Overseas Shipholding Group shares climbed 22.8% to $8.43 on Monday. Here are some other big stocks recording gains in today's session. Hims & Hers Health, Inc. (NYSE:HIMS) shares jumped 30.5% to $19.01 after the company announced the addition of GLP-1 injections to it
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.